CAJ | 학술논문

目的：观察亚砷酸(ATO)联合反应停、维生素C (VitC)治疗难治性复发性多发性骨髓瘤(MM)的疗效及安全性。方法：19例难治复发MM患者，应用亚砷酸(10mg/d)联合反应停(200～300mg/d)、VitC(2g/d)，连用4周。结果：部分缓解(PR)47%，疾病稳定(SD)32%，疾病进展(PD)21%。主要不良反应为白细胞减少、消化道反应及肝功能损害。结论：ATO联合反应停、VitC治疗难治性复发性MM有效率较高，且毒副反应低，很有临床应用前景。
목적：관찰아신산(ATO)연합반응정、유생소C (VitC)치료난치성복발성다발성골수류(MM)적료효급안전성。방법：19례난치복발MM환자，응용아신산(10mg/d)연합반응정(200～300mg/d)、VitC(2g/d)，련용4주。결과：부분완해(PR)47%，질병은정(SD)32%，질병진전(PD)21%。주요불량반응위백세포감소、소화도반응급간공능손해。결론：ATO연합반응정、VitC치료난치성복발성MM유효솔교고，차독부반응저，흔유림상응용전경。
Objective: To observe the efficacy and side effects of arsenic trioxide(ATO) and Thalidomide、ascorbic acid(VitC)in the treatment of relapsed or refractory multiple myeloma (MM). Methods: patients with relapsed or refractory MM were treated by ATO(10 mg/d)and Thalidomide(200~300 mg/d) 、VitC(2g/d) lasting 4 weeks.Results: The partial remission(PR) rate was 47%. The stable disease(SD) rate was 32% and the progressive disease(PD) rate was 21%. The main side effects were leukocytopenia, digestive tract reaction and liver function damage. Conclusion: The regiment(ATO+ Thalidomide+ VitC) is effective and low adverse reaction for the treatment of relapsed or refractory MM.It has a prospect of clinical application.